Better Buy: Eli Lilly and Company vs. AbbVie
A less-than-surprising clinical failure recently sent Eli Lilly & Co. (NYSE:LLY) shares tumbling, while AbbVie (NYSE:ABBV) stock has traded sideways for most of the year. Since spinning off from its parent, Abbott, AbbVie has made an impressive effort to diversify its revenue stream away from the world’s best-selling drug before it loses patent protection. Eli Lilly […]Read More